Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

A number of other research firms also recently issued reports on CTLT. KeyCorp raised Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 price target for the company in a research report on Wednesday, March 28th. ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. UBS Group raised Catalent from a “market perform” rating to an “outperform” rating in a research report on Wednesday, March 21st. Finally, Raymond James raised Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a research report on Wednesday, March 21st. They noted that the move was a valuation call. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $45.67.

CTLT stock traded up $0.19 during trading on Tuesday, reaching $42.01. 359,600 shares of the stock traded hands, compared to its average volume of 953,891. Catalent has a 52-week low of $33.42 and a 52-week high of $47.87. The company has a current ratio of 2.18, a quick ratio of 1.78 and a debt-to-equity ratio of 2.53. The company has a market cap of $5.59 billion, a PE ratio of 31.12, a price-to-earnings-growth ratio of 2.04 and a beta of 1.49.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, May 1st. The company reported $0.41 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.06. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The firm had revenue of $627.90 million during the quarter, compared to the consensus estimate of $610.47 million. During the same quarter in the previous year, the business earned $0.38 earnings per share. The firm’s quarterly revenue was up 17.9% compared to the same quarter last year. equities analysts forecast that Catalent will post 1.55 EPS for the current fiscal year.

In other Catalent news, SVP Steven L. Fasman sold 2,252 shares of the business’s stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $41.78, for a total transaction of $94,088.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.70% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Brown Advisory Inc. lifted its stake in shares of Catalent by 1.7% in the first quarter. Brown Advisory Inc. now owns 2,065,531 shares of the company’s stock worth $84,811,000 after acquiring an additional 33,576 shares in the last quarter. Diversified Trust Co lifted its stake in shares of Catalent by 26.4% in the first quarter. Diversified Trust Co now owns 10,905 shares of the company’s stock worth $448,000 after acquiring an additional 2,280 shares in the last quarter. Allianz Asset Management GmbH lifted its stake in shares of Catalent by 0.3% in the first quarter. Allianz Asset Management GmbH now owns 710,919 shares of the company’s stock worth $29,190,000 after acquiring an additional 2,021 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of Catalent by 1.8% in the first quarter. Principal Financial Group Inc. now owns 581,638 shares of the company’s stock worth $23,882,000 after acquiring an additional 10,249 shares in the last quarter. Finally, Summit Trail Advisors LLC lifted its stake in shares of Catalent by 2,021.9% in the first quarter. Summit Trail Advisors LLC now owns 103,210 shares of the company’s stock worth $103,000 after acquiring an additional 98,346 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.